"10.1371_journal.pone.0057222","plos one","2013-02-28T00:00:00Z","Linong Ji; Hongmei Li; Xiaohui Guo; Yan Li; Renming Hu; Zhengying Zhu","Department of Endocrinology and Metabolism, Peking University Peoples Hospital, Beijing, China; Clinical Research, China Research & Development, Sino-American Shanghai Squibb Pharmaceutical Ltd, Shanghai, China; Department of Endocrinology, Peking University First Hospital, Beijing, China; Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China; Clinical Research, China Research & Development, Bristol-Myers Squibb, Shanghai, China","Reviewed and approved the manuscript: LJ HL XG YL RH ZZ. Conceived and designed the experiments: LJ. Performed the experiments: LJ HL XG YL RH. Analyzed the data: LJ HL XG ZZ. Wrote the paper: LJ HL ZZ.","The authors LJ, XG and RH have received honoraria for attending Advisory Board meetings for Bristol-Myers Squibb and have received payment for lectures. LJ and XG are investigators in clinical trials of other compounds under development by Bristol-Myers Squibb. ZZ is an employee of Bristol-Myers Squibb and has received stock/stock options from Bristol-Myers Squibb. This study was funded by Bristol-Myers Squibb. Statistical analyses were performed by MJ and XK of Pharmaceutical Product Development, Inc., paid for by Bristol-Myers Squibb. Editorial assistance with preparation of the manuscript was provided by Samantha Santangelo, PhD, of MediTech Media Asia Pacific Pte Ltd, paid for by Bristol-Myers Squibb. HL is an employee of Sino-American Shanghai Squibb Pharmaceutical Ltd. Metformin which was used in this study is a product of Bristol-Myers Squibb. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","02","Linong Ji","LJ",6,TRUE,1,5,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
